Compare Hims and Hers Health Inc (HIMS) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Western Alliance Bancorporation — how do they compare? Hims and Hers Health Inc trades at $29.22 (market cap $6.55B), while Western Alliance Bancorporation trades at $74.43 (market cap $8.24B). The key difference: Western Alliance Bancorporation is the larger of the two by market cap, and Western Alliance Bancorporation pays a 2.23% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Western Alliance Bancorporation for 3 Days on average.
| HIMS | WAL | |
|---|---|---|
Market Cap | $6.55B | $8.24B |
Volume | 14,842,814 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $62.76 | $96.08 |
52-Week Low | $14.52 | $66.70 |
Typical Hold Time | 21 Days | 3 Days |
Enterprise Value | $7.25B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Western Alliance Bancorporation (WAL) trades at $74.22, down 0.17% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.52 and net income margin of 25.43%, while recent earnings have mostly beaten expectations. The company launched WA VenueX, an institutional financial platform, signaling innovation in digital banking services. Analyst consensus is strongly bullish with a $84.33 price target, though technical indicators suggest near-term caution.
WAL presents a compelling value opportunity with attractive valuation multiples and solid profitability, but faces headwinds from bearish technical trends and interest rate sensitivity. The stock's upside hinges on continued earnings growth and successful execution of new initiatives like WA VenueX, while regulatory changes and economic conditions remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
